Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations
The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG . Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still rema...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2018-02, Vol.8 (1), p.3246-9, Article 3246 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 9 |
---|---|
container_issue | 1 |
container_start_page | 3246 |
container_title | Scientific reports |
container_volume | 8 |
creator | Lempens, Pauline Meehan, Conor J. Vandelannoote, Koen Fissette, Kristina de Rijk, Pim Van Deun, Armand Rigouts, Leen de Jong, Bouke C. |
description | The majority of
Mycobacterium tuberculosis
isolates resistant to isoniazid harbour a mutation in
katG
. Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still remain partly active in presence of a
katG
mutation. We therefore investigated which genetic mutations predict the level of phenotypic isoniazid resistance in clinical
M. tuberculosis
isolates. To this end, the association between known and unknown isoniazid resistance-conferring mutations in whole genome sequences, and the isoniazid MICs of 176 isolates was examined. We found mostly moderate-level resistance characterized by a mode of 6.4 mg/L for the very common
katG
Ser315Thr mutation, and always very high MICs (≥19.2 mg/L) for the combination of
katG
Ser315Thr and
inhA
c-15t. Contrary to common belief, isolates harbouring
inhA
c-15t alone, partly also showed moderate-level resistance, particularly when combined with
inhA
Ser94Ala. No overt association between low-confidence or unknown mutations, except in
katG
, and isoniazid resistance (level) was found. Except for the rare
katG
deletion, line probe assay is thus not sufficiently accurate to predict the level of isoniazid resistance for a single mutation in
katG
or
inhA
. |
doi_str_mv | 10.1038/s41598-018-21378-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5818527</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2004118262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-e5b4443e3e1960c190480bfc9b67bfac5f676b54f0e0df84815cd1089fdc4e073</originalsourceid><addsrcrecordid>eNp9kcFuFSEUhidGY5vaF3BhSNy4GQUGZmBjYpqqTWrc6JoAc7iXhoErzDS97n1vmd7aVheyOQQ-Pjj8TfOS4LcEd-JdYYRL0WIiWkq6QbQ3T5pjihlvaUfp00fzo-a0lCtcB6eSEfm8OaqVy76Xx82vi5Ki1z_9iDIUX2YdLaAA1xAKSg592dtktJ0h-2VC82Ig2yWkSiKrIwo6byDskQG0yzD6Co7I7NHWb7atTdH5EVbhg_t2FXL2cYOmZdazT7G8aJ45HQqc3tWT5vvH829nn9vLr58uzj5ctpYTMrfADWOsgw6I7LElEjOBjbPS9INx2nLXD73hzGHAoxNMEG5HgoV0o2WAh-6keX_w7hYzwWghzlkHtct-0nmvkvbq753ot2qTrhUXRHC6Ct7cCXL6sUCZ1eSLhRB0hLQURTEeCOkHIiv6-h_0Ki051vZWihEiaE8rRQ-UzamUDO7-MQSrNWh1CFrVoNVt0OqmHnr1uI37I39irUB3AMpu_WjID3f_R_sbz824mQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2004118262</pqid></control><display><type>article</type><title>Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Lempens, Pauline ; Meehan, Conor J. ; Vandelannoote, Koen ; Fissette, Kristina ; de Rijk, Pim ; Van Deun, Armand ; Rigouts, Leen ; de Jong, Bouke C.</creator><creatorcontrib>Lempens, Pauline ; Meehan, Conor J. ; Vandelannoote, Koen ; Fissette, Kristina ; de Rijk, Pim ; Van Deun, Armand ; Rigouts, Leen ; de Jong, Bouke C.</creatorcontrib><description>The majority of
Mycobacterium tuberculosis
isolates resistant to isoniazid harbour a mutation in
katG
. Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still remain partly active in presence of a
katG
mutation. We therefore investigated which genetic mutations predict the level of phenotypic isoniazid resistance in clinical
M. tuberculosis
isolates. To this end, the association between known and unknown isoniazid resistance-conferring mutations in whole genome sequences, and the isoniazid MICs of 176 isolates was examined. We found mostly moderate-level resistance characterized by a mode of 6.4 mg/L for the very common
katG
Ser315Thr mutation, and always very high MICs (≥19.2 mg/L) for the combination of
katG
Ser315Thr and
inhA
c-15t. Contrary to common belief, isolates harbouring
inhA
c-15t alone, partly also showed moderate-level resistance, particularly when combined with
inhA
Ser94Ala. No overt association between low-confidence or unknown mutations, except in
katG
, and isoniazid resistance (level) was found. Except for the rare
katG
deletion, line probe assay is thus not sufficiently accurate to predict the level of isoniazid resistance for a single mutation in
katG
or
inhA
.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-018-21378-x</identifier><identifier>PMID: 29459669</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>45/22 ; 45/23 ; 631/208/205 ; 631/326/22/1434 ; 631/326/2521 ; 631/326/41/2530 ; 631/326/421 ; Antitubercular Agents - pharmacology ; Bacterial Proteins - genetics ; Catalase - genetics ; Drug Resistance, Bacterial ; Genomes ; Humanities and Social Sciences ; Humans ; Isoniazid ; Isoniazid - pharmacology ; Microbial Sensitivity Tests ; multidisciplinary ; Mutation ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - genetics ; Mycobacterium tuberculosis - isolation & purification ; Oxidoreductases - genetics ; Science ; Science (multidisciplinary) ; Tuberculosis ; Tuberculosis - microbiology</subject><ispartof>Scientific reports, 2018-02, Vol.8 (1), p.3246-9, Article 3246</ispartof><rights>The Author(s) 2018</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-e5b4443e3e1960c190480bfc9b67bfac5f676b54f0e0df84815cd1089fdc4e073</citedby><cites>FETCH-LOGICAL-c511t-e5b4443e3e1960c190480bfc9b67bfac5f676b54f0e0df84815cd1089fdc4e073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818527/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818527/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27928,27929,41124,42193,51580,53795,53797</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29459669$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lempens, Pauline</creatorcontrib><creatorcontrib>Meehan, Conor J.</creatorcontrib><creatorcontrib>Vandelannoote, Koen</creatorcontrib><creatorcontrib>Fissette, Kristina</creatorcontrib><creatorcontrib>de Rijk, Pim</creatorcontrib><creatorcontrib>Van Deun, Armand</creatorcontrib><creatorcontrib>Rigouts, Leen</creatorcontrib><creatorcontrib>de Jong, Bouke C.</creatorcontrib><title>Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>The majority of
Mycobacterium tuberculosis
isolates resistant to isoniazid harbour a mutation in
katG
. Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still remain partly active in presence of a
katG
mutation. We therefore investigated which genetic mutations predict the level of phenotypic isoniazid resistance in clinical
M. tuberculosis
isolates. To this end, the association between known and unknown isoniazid resistance-conferring mutations in whole genome sequences, and the isoniazid MICs of 176 isolates was examined. We found mostly moderate-level resistance characterized by a mode of 6.4 mg/L for the very common
katG
Ser315Thr mutation, and always very high MICs (≥19.2 mg/L) for the combination of
katG
Ser315Thr and
inhA
c-15t. Contrary to common belief, isolates harbouring
inhA
c-15t alone, partly also showed moderate-level resistance, particularly when combined with
inhA
Ser94Ala. No overt association between low-confidence or unknown mutations, except in
katG
, and isoniazid resistance (level) was found. Except for the rare
katG
deletion, line probe assay is thus not sufficiently accurate to predict the level of isoniazid resistance for a single mutation in
katG
or
inhA
.</description><subject>45/22</subject><subject>45/23</subject><subject>631/208/205</subject><subject>631/326/22/1434</subject><subject>631/326/2521</subject><subject>631/326/41/2530</subject><subject>631/326/421</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Bacterial Proteins - genetics</subject><subject>Catalase - genetics</subject><subject>Drug Resistance, Bacterial</subject><subject>Genomes</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Isoniazid</subject><subject>Isoniazid - pharmacology</subject><subject>Microbial Sensitivity Tests</subject><subject>multidisciplinary</subject><subject>Mutation</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - genetics</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Oxidoreductases - genetics</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Tuberculosis</subject><subject>Tuberculosis - microbiology</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kcFuFSEUhidGY5vaF3BhSNy4GQUGZmBjYpqqTWrc6JoAc7iXhoErzDS97n1vmd7aVheyOQQ-Pjj8TfOS4LcEd-JdYYRL0WIiWkq6QbQ3T5pjihlvaUfp00fzo-a0lCtcB6eSEfm8OaqVy76Xx82vi5Ki1z_9iDIUX2YdLaAA1xAKSg592dtktJ0h-2VC82Ig2yWkSiKrIwo6byDskQG0yzD6Co7I7NHWb7atTdH5EVbhg_t2FXL2cYOmZdazT7G8aJ45HQqc3tWT5vvH829nn9vLr58uzj5ctpYTMrfADWOsgw6I7LElEjOBjbPS9INx2nLXD73hzGHAoxNMEG5HgoV0o2WAh-6keX_w7hYzwWghzlkHtct-0nmvkvbq753ot2qTrhUXRHC6Ct7cCXL6sUCZ1eSLhRB0hLQURTEeCOkHIiv6-h_0Ki051vZWihEiaE8rRQ-UzamUDO7-MQSrNWh1CFrVoNVt0OqmHnr1uI37I39irUB3AMpu_WjID3f_R_sbz824mQ</recordid><startdate>20180219</startdate><enddate>20180219</enddate><creator>Lempens, Pauline</creator><creator>Meehan, Conor J.</creator><creator>Vandelannoote, Koen</creator><creator>Fissette, Kristina</creator><creator>de Rijk, Pim</creator><creator>Van Deun, Armand</creator><creator>Rigouts, Leen</creator><creator>de Jong, Bouke C.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180219</creationdate><title>Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations</title><author>Lempens, Pauline ; Meehan, Conor J. ; Vandelannoote, Koen ; Fissette, Kristina ; de Rijk, Pim ; Van Deun, Armand ; Rigouts, Leen ; de Jong, Bouke C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-e5b4443e3e1960c190480bfc9b67bfac5f676b54f0e0df84815cd1089fdc4e073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>45/22</topic><topic>45/23</topic><topic>631/208/205</topic><topic>631/326/22/1434</topic><topic>631/326/2521</topic><topic>631/326/41/2530</topic><topic>631/326/421</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Bacterial Proteins - genetics</topic><topic>Catalase - genetics</topic><topic>Drug Resistance, Bacterial</topic><topic>Genomes</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Isoniazid</topic><topic>Isoniazid - pharmacology</topic><topic>Microbial Sensitivity Tests</topic><topic>multidisciplinary</topic><topic>Mutation</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - genetics</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Oxidoreductases - genetics</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Tuberculosis</topic><topic>Tuberculosis - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lempens, Pauline</creatorcontrib><creatorcontrib>Meehan, Conor J.</creatorcontrib><creatorcontrib>Vandelannoote, Koen</creatorcontrib><creatorcontrib>Fissette, Kristina</creatorcontrib><creatorcontrib>de Rijk, Pim</creatorcontrib><creatorcontrib>Van Deun, Armand</creatorcontrib><creatorcontrib>Rigouts, Leen</creatorcontrib><creatorcontrib>de Jong, Bouke C.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lempens, Pauline</au><au>Meehan, Conor J.</au><au>Vandelannoote, Koen</au><au>Fissette, Kristina</au><au>de Rijk, Pim</au><au>Van Deun, Armand</au><au>Rigouts, Leen</au><au>de Jong, Bouke C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2018-02-19</date><risdate>2018</risdate><volume>8</volume><issue>1</issue><spage>3246</spage><epage>9</epage><pages>3246-9</pages><artnum>3246</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>The majority of
Mycobacterium tuberculosis
isolates resistant to isoniazid harbour a mutation in
katG
. Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still remain partly active in presence of a
katG
mutation. We therefore investigated which genetic mutations predict the level of phenotypic isoniazid resistance in clinical
M. tuberculosis
isolates. To this end, the association between known and unknown isoniazid resistance-conferring mutations in whole genome sequences, and the isoniazid MICs of 176 isolates was examined. We found mostly moderate-level resistance characterized by a mode of 6.4 mg/L for the very common
katG
Ser315Thr mutation, and always very high MICs (≥19.2 mg/L) for the combination of
katG
Ser315Thr and
inhA
c-15t. Contrary to common belief, isolates harbouring
inhA
c-15t alone, partly also showed moderate-level resistance, particularly when combined with
inhA
Ser94Ala. No overt association between low-confidence or unknown mutations, except in
katG
, and isoniazid resistance (level) was found. Except for the rare
katG
deletion, line probe assay is thus not sufficiently accurate to predict the level of isoniazid resistance for a single mutation in
katG
or
inhA
.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>29459669</pmid><doi>10.1038/s41598-018-21378-x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2045-2322 |
ispartof | Scientific reports, 2018-02, Vol.8 (1), p.3246-9, Article 3246 |
issn | 2045-2322 2045-2322 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5818527 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
subjects | 45/22 45/23 631/208/205 631/326/22/1434 631/326/2521 631/326/41/2530 631/326/421 Antitubercular Agents - pharmacology Bacterial Proteins - genetics Catalase - genetics Drug Resistance, Bacterial Genomes Humanities and Social Sciences Humans Isoniazid Isoniazid - pharmacology Microbial Sensitivity Tests multidisciplinary Mutation Mycobacterium tuberculosis Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - genetics Mycobacterium tuberculosis - isolation & purification Oxidoreductases - genetics Science Science (multidisciplinary) Tuberculosis Tuberculosis - microbiology |
title | Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T14%3A17%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Isoniazid%20resistance%20levels%20of%20Mycobacterium%20tuberculosis%20can%20largely%20be%20predicted%20by%20high-confidence%20resistance-conferring%20mutations&rft.jtitle=Scientific%20reports&rft.au=Lempens,%20Pauline&rft.date=2018-02-19&rft.volume=8&rft.issue=1&rft.spage=3246&rft.epage=9&rft.pages=3246-9&rft.artnum=3246&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-018-21378-x&rft_dat=%3Cproquest_pubme%3E2004118262%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2004118262&rft_id=info:pmid/29459669&rfr_iscdi=true |